



## Comprehensive Genomic Profiling for Metastatic Breast Cancer: Current Status and Future Perspectives

Guest Editors:

**Dr. Hiroshi Tada**

Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai 980-8575, Japan

**Dr. Hiroko Masuda**

Department of Breast Surgical Oncology, School of Medicine, Showa University, Tokyo 142-8666, Japan

Deadline for manuscript submissions:

**closed (30 September 2024)**

### Message from the Guest Editors

Over the past 20 years, advances in genomic analysis of breast cancer have allowed for the constant evolution of clinically relevant subtypes, from immunohistochemically defined groups to molecular profiles. Advanced comprehensive genomic profiling and multiple targeted therapeutics promoted research on molecular tumor characteristics and led to the development of a new approach for metastatic breast cancer (mBC). Broad implementation of comprehensive genomic profiling across an institution is feasible. During this period, the number of genotype selection trials for breast cancer has steadily increased.

While several independent studies suggest better outcomes for the use of molecularly targeted agents compared to conventional therapies, others did not improve outcomes. These conflicting results highlight one of the major problems in precision oncology: the accurate practical interpretation of biomarkers for patient selection.

There are still new opportunities for the improvement of precision medicine for mBC, as evidence supporting this approach is still missing.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)